Alantra buys three genomics businesses

Alantra will control a 55% stake in the new group, while the management teams of the three companies acquired will retain significant stakes in the new platform and continue to lead their businesses.

With four operating centres in Valencia, A Coruña, Madrid and Malaga, the resulting group will employ around 160 staff and generate aggregate revenues of €25m.

The three companies are complementary and all their workforce, operating centres and laboratories will be preserved and integrated, according to Alantra.

Imegen's majority shareholder, Qualitas Equity Partners, reinvested in the company alongside Alantra. Qualitas had acquired a stake in Imegen in March 2017 via its Q-Growth fund, in a deal valuing the business at around €10m.

Alantra is currently investing its Alantra PEF III fund, which held a final close on €450m in February 2017 and is now around 50% deployed.

Company
Imegen, Genycell and Health in Code specialise in genetic diagnosis and genomics research. They employ 160 staff across their four centres based in Valencia, A Coruña, Madrid and Malaga, and generate combined revenues of €25m.

People
Alantra Private Equity – David Santos (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Southern Europe
• Healthcare
• Alantra Private Equity
• Spain